Cerevel Therapeutics Holdings Inc.
| NASDAQ: CERE | Healthcare / Biotechnology / USA |
| 13.57 | +0.1900 | +1.42% | Vol 226.92K | 1Y Perf 13.45% |
| Jun 14th, 2021 16:00 DELAYED |
| BID | 12.38 | ASK | 13.55 | ||
| Open | 13.32 | Previous Close | 13.38 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 21.50 | Analyst Rating | — — 0.00 | |
| Potential % | 58.44 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 1.73B | Earnings Rating | — | |
| Price Range Ratio 52W % | 46.49 | Earnings Date | 17th May 2021 |
Today's Price Range 13.3013.73 | 52W Range 9.0018.83 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.04% | ||
| 1 Month | -0.22% | ||
| 3 Months | -13.95% | ||
| 6 Months | -21.06% | ||
| 1 Year | 13.45% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -44.09 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -36.73 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -39.97 | |||
Return on invested Capital Q | -12.87 | |||
Return on invested Capital Y | -58.18 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -6.70 | ||||
| 5.02 | ||||
| - | ||||
| - | ||||
| -11.50 | ||||
| -0.98 | ||||
| 5.02 | ||||
| 2.67 | ||||
| 1.40B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.10 | ||||
| 10.20 | ||||
| 0.09 | ||||
| 0.10 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | - | -4.83 | - |
| Q01 2021 | -0.45 | -0.40 | 11.11 |
| Q04 2020 | -0.37 | -0.27 | 27.03 |
| Q03 2016 | - | -0.08 | - |
| Q02 2016 | - | -0.09 | - |
| Q01 2016 | - | -0.39 | - |
| Q04 2015 | - | -1.26 | - |
| Q03 2015 | - | -0.98 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.45 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 226.92K |
| Shares Outstanding | 127.46M |
| Trades Count | 2.17K |
| Dollar Volume | 1.96M |
| Avg. Volume | 232.73K |
| Avg. Weekly Volume | 237.65K |
| Avg. Monthly Volume | 247.25K |
| Avg. Quarterly Volume | 241.26K |
Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) stock closed at 13.57 per share at the end of the most recent trading day (a 1.42% change compared to the prior day closing price) with a volume of 226.92K shares and market capitalization of 1.73B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 104 people. Cerevel Therapeutics Holdings Inc. CEO is N. Anthony Coles.
The one-year performance of Cerevel Therapeutics Holdings Inc. stock is 13.45%, while year-to-date (YTD) performance is -18.15%. CERE stock has a five-year performance of %. Its 52-week range is between 9 and 18.83, which gives CERE stock a 52-week price range ratio of 46.49%
Cerevel Therapeutics Holdings Inc. currently has a PE ratio of -6.70, a price-to-book (PB) ratio of 5.02, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.73%, a ROC of -39.97% and a ROE of -44.09%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cerevel Therapeutics Holdings Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Cerevel Therapeutics Holdings Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cerevel Therapeutics Holdings Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cerevel Therapeutics Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cerevel Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cerevel Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.16, ATR14 : 0.82, CCI20 : -48.49, Chaikin Money Flow : 0.02, MACD : -0.06, Money Flow Index : 60.95, ROC : 2.03, RSI : 48.56, STOCH (14,3) : 35.87, STOCH RSI : 0.21, UO : 40.83, Williams %R : -64.13), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cerevel Therapeutics Holdings Inc. in the last 12-months were:
Cerevel Therapeutics Holdings Inc.
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
CEO: N. Anthony Coles
Telephone: +1 844 304-2048
Address: 222 Jacobs Street, Cambridge 02141, MA, US
Number of employees: 104
